The Effect Of Nanoherbal Solanum Lycopersicum On Rat Induced Streptozotocin
Keywords:Solanum lycopersicum, nano formulation, diabetes mellitus, oxidative stress, insulin
Abstract : Diabetes Mellitus (DM) has become a global health threat in the 21st century. DM sufferers are increasing, according to the International Diabetes Federation (IDF) in 2017, the number of DM sufferers in the world is 7.5 million people and is predicted to be 9.5 million in 2017. In 2045, Indonesia itself was ranked 7th out of 10 countries with the most DM at the age of 20-79 years and ranked 4th out of 10 countries with the largest population of undiagnosed. This study aim to determine the antihyperglycemia activity of Nanoherbal Extract of Solanum lycopersicum. This is an experimental study in which the research group was divided into seven groups, each including five rats weighing 200-250 grams. Which are (normal group, negative group, metformin, nanoherbal 25, 50, 100, and 200 mg/kgBW). Rats were induced by STZ 55 mg/kgBW + NCT 120 mg/kgBW until the blood glucose is above 200 mg/dL. The highest level of SOD is the control group 63.984 ± 2,065 ng/mL and the lowest is negative group is 18,173 ± 2,130 ng/mL. For group that given treatment show that the highest SOD level is in dose 200 mg/kgBW 77,603 ± 3,089 ng/mL and the lowest is in dose 25 mg/kgBW 33,612 ± 1,477 ng/mL and the group given metformin is 69,546 ± 3,128 ng/mL. The highest level of Insulin is the control group 305,573 ± 5,51ng/mL and the lowest is negative group is 48,5366 ± 2,44 ng/mL. For group that given treatment show that the highest insulin level is in dose 200 mg/kgBW 305,939 ± 4,999 ng/mL and the lowest is in dose 25 mg/kgBW 73,938 ± 4,38 ng/mL and the group given metformin is 300,176 ± 10,072 ng/mL. Nanoherbal of Solanum lycopersicum has antihyperglycemia activity by increasing the level of insulin and SOD.
Gupta AK, Ganguly P, Majumder UK, Ghosal S. Antidiabetic and antihyperlipidaemic effects of Solanum xanthocarpum total extract in alloxan induced diabetic rats. Pharmacologyonline. 2009;1:484-97.
King GL, Loeken MR. Hyperglycemia-induced oxidative stress in diabetic complications. Histochemistry and cell biology. 2004;122(4):333-8.
Kerby JD, Griffin RL, MacLennan P, Rue III LW. Stress-induced hyperglycemia, not diabetic hyperglycemia, is associated with higher mortality in trauma. Annals of surgery. 2012; 256(3):446-52.
Furnary AP, Wu Y. Clinical effects of hyperglycemia in the cardiac surgery population: the Portland Diabetic Project. Endocrine Practice. 2006;12:22-6.
Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease: the case for transforming growth factor–β as a key mediator. Diabetes. 1995;44(10):1139-46.
Nyengaard JR, Ido Y, Kilo C, Williamson JR. Interactions between hyperglycemia and hypoxia: implications for diabetic retinopathy. Diabetes. 2004;53(11):2931-8.
Choi JS, Yokozawa T, Oura H. Improvement of hyperglycemia and hyperlipemia in streptozotocin-diabetic rats by a methanolic extract of Prunus davidiana stems and its main component, prunin. Planta medica. 1991;57(03):208-11.
Maiti R, Das UK, Ghosh D. Attenuation of hyperglycemia and hyperlipidemia in streptozotocin-induced diabetic rats by aqueous extract of seed of Tamarindus indica. Biological and Pharmaceutical Bulletin. 2005;28(7):1172-6.
Li Y, Wen S, Kota BP, Peng G, Li GQ, Yamahara J, Roufogalis BD. Punica granatum flower extract, a potent α-glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats. Journal of Ethnopharmacology. 2005;99(2):239-44.
Elberry AA, Harraz FM, Ghareib SA, Gabr SA, Nagy AA, Abdel-Sattar E. Methanolic extract of Marrubium vulgare ameliorates hyperglycemia and dyslipidemia in streptozotocin-induced diabetic rats. International journal of diabetes mellitus. 2015;3(1):37-44.
How to Cite
Copyright (c) 2022 Djohan Djohan, Bungaran Sihombing, Sahna Ferdinand, Hanjaya Hanjaya
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
n order for Proceedings of Malikussaleh International Conference on Health and Disaster Medicine (MICOHEDMED) to publish and disseminate research articles, we need non-exclusive publishing rights (transfered from author(s) to publisher). This is determined by a publishing agreement between the Author(s) and Proceedings of Malikussaleh International Conference on Health and Disaster Medicine (MICOHEDMED). This agreement deals with the transfer or license of the copyright of publishing to Proceedings of Malikussaleh International Conference on Health and Disaster Medicine (MICOHEDMED), while Authors still retain significant rights to use and share their own published articles. Proceedings of Malikussaleh International Conference on Health and Disaster Medicine (MICOHEDMED) supports the need for authors to share, disseminate and maximize the impact of their research and these rights, in any databases.
As a proceeding Author, you have rights for a large range of uses of your article, including use by your employing institute or company. These Author rights can be exercised without the need to obtain specific permission. Authors publishing in Proceedings of Malikussaleh International Conference on Health and Disaster Medicine (MICOHEDMED) proceedings have wide rights to use their works for teaching and scholarly purposes without needing to seek permission, including:
- use for classroom teaching by Author or Author's institution and presentation at a meeting or conference and distributing copies to attendees;
- use for internal training by author's company;
- distribution to colleagues for their reseearch use;
- use in a subsequent compilation of the author's works;
- inclusion in a thesis or dissertation;
- reuse of portions or extracts from the article in other works (with full acknowledgement of final article);
- preparation of derivative works (other than commercial purposes) (with full acknowledgement of final article);
- voluntary posting on open web sites operated by author or author’s institution for scholarly purposes,
(but it should follow the open access license of Creative Common CC-by-SA License).
Authors/Readers/Third Parties can read, print and download, redistribute or republish the article (e.g. display in a repository), translate the article, download for text and data mining purposes, reuse portions or extracts from the article in other works, sell or re-use for commercial purposes, remix, transform, or build upon the material, they must distribute their contributions under the same license as the original Creative Commons Attribution-ShareAlike (CC BY-SA).